Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Lori Ann Leslie"'
Autor:
Jason Westin, Frederick L. Locke, Michael Dickinson, Armin Ghobadi, Mahmoud Elsawy, Tom van Meerten, David Bernard Miklos, Matthew Ulrickson, Miguel-Angel Perales, Umar Farooq, Luciano Wannesson, Lori Ann Leslie, Marie José Kersten, Caron Alyce Jacobson, John M. Pagel, Gerald Wulf, Linqiu Du, Julia Snider, Christina Ann To, Olalekan O. Oluwole
Publikováno v:
Journal of Clinical Oncology. 40:7548-7548
7548 Background: Elderly pts with R/R LBCL are at risk of inferior outcomes, increased toxicity, and inability to tolerate second-line (2L) SOC treatment (Tx) (Di M, et al. Oncologist. 2021). Further 2L SOC Tx is often associated with poor health-rel
Autor:
Erel Joffe, Grzegorz S. Nowakowski, Han W. Tun, Allison Claire Rosenthal, Matthew Alexander Lunning, Radhakrishnan Ramchandren, Chia-Cheng Li, Li Zhou, Elizabeth Martinez, Reinhard W. Von Roemeling, Robert H. Earhart, Meaghan McMahon, Iris Isufi, Lori Ann Leslie
Publikováno v:
Journal of Clinical Oncology. 40:7575-7575
7575 Background: CA-4948 is a novel oral inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4), which is essential for toll-like receptor (TLR) and interleukin-1 receptor (IL-1R) signaling in B cell proliferation. IRAK4 forms a Myddosome co
Autor:
Paolo Strati, Lori Ann Leslie, Parveen Shiraz, L Elizabeth Budde, Olalekan O. Oluwole, Matthew Ulrickson, Aravind Ramakrishnan, Jennifer Sun, Rhine Shen, Justyna Kanska, Peter McCroskery, Jinghui Dong, Marco Andreas Schupp, Hairong Xu, Krish Patel
Publikováno v:
Journal of Clinical Oncology. 40:7567-7567
7567 Background: Despite the success of axi-cel, ≈60% of patients (pts) have no response or relapse within ̃2 y after Tx (Jacobson C, et al. ASH 2021. #1764), highlighting the need for more therapeutic strategies. In preclinical studies, Rtx augme